Avalanche rides gene therapy to $55 million Series B round

Avalanche Biotechnologies Inc., whose experimental gene therapy potentially could stop a blinding eye disease with a single shot, scored $55 million in Series B funding from a team of investors, the company said Tuesday...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.